This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer.

A Phase 1a/b, First-in-Human Dose Escalation and Dose Expansion Clinical Study of the Dual Targeting Trop-2 and Nectin-4 Multibody Drug Conjugate BD200 in Participants With Select Unresectable Locally Advanced or Metastatic Cancers

The Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of BD200 in adult participants with advanced solid cancers. This is an open-label study consisting of two-parts: Part A Dose Escalation and Part B Dose Expansion. At least one tumor-specific cohort will be selected in Part B Dose Expansion.

Inclusion Criteria:

• Age 18+ years
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Participant willing to provide tumor biopsies
• Measurable disease per RECIST v1.1
• Histologically-confirmed advanced, metastatic, or recurrent solid tumors that is not amenable to surgical resection or other approved therapeutic options
• Satisfy requirements for prior treatments per tumor type as outlined in the protocol
• Adequate organ function
• Agree to contraception requirements as outlined in the protocol

Exclusion Criteria:

• Any major surgery or traumatic injury prior to enrollment
• Unhealed wounds from surgery or injury
• Received other therapies within 4 weeks prior to enrollment
• Any clinically significant chronic gastrointestinal (GI) disorder
• Any clinically significant ascites or liver disease
• Any clinically significant pulmonary compromise
• Active infection at the time enrollment
• Active autoimmune disease
• History or active skin disease requiring frequent treatment
• Any clinically significant corneal disorder
• Active known second malignancy
• Any clinically significant cardiac disease
• Participants with tumor abutting or eroding a major vessel
• Pregnant or lactating or planning to become pregnant
• Known hypersensitivity to BD200 or any of its ingredients
• Unresolved toxicities from previous anticancer therapy
• Participation in a concurrent clinical study in the treatment period
• Part A Only: Participant with hepatitis B virus (HBV), hepatitis virus (HCV) or human immunodeficiency virus (HIV) infection

Note: Other inclusion and exclusion criteria may apply.